Maxigen Biotech Inc. Statistics
Maxigen Biotech Inc. (1783) Stock Statistics & Valuation Metrics
Total Valuation
Maxigen Biotech Inc. has a market cap or net worth of TWD 3.11B. The enterprise value is TWD 2.60B.
- Market Cap
- TWD 3.11B
- Enterprise Value
- TWD 2.60B
Share Statistics
Maxigen Biotech Inc. has 89,698,110 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 89,698,110
- Owned by Insiders
- ―
- Owned by Institutions
- 0.12%
Financial Efficiency
Maxigen Biotech Inc.’s return on equity (ROE) is 0.17 and return on invested capital (ROIC) is 13.81%.
- Return on Equity (ROE)
- 0.17
- Return on Assets (ROA)
- 0.14
- Return on Invested Capital (ROIC)
- 13.81%
- Return on Capital Employed (ROCE)
- 0.17
- Revenue Per Employee
- 6.39M
- Profits Per Employee
- 2.09M
- Employee Count
- 127
- Asset Turnover
- 0.43
- Inventory Turnover
- 2.50
Valuation Ratios
The current PE Ratio of Maxigen Biotech Inc. is 9.18. Maxigen Biotech Inc.’s PEG ratio is 0.14.
- PE Ratio
- 9.18
- PS Ratio
- 3.78
- PB Ratio
- 1.27
- Price to FCF
- 13.10
- Price to Operating Cash Flow
- 5.71
- PEG Ratio
- 0.14
Income Statement
In the last 12 months, Maxigen Biotech Inc. had revenue of 811.56M and earned 265.31M in profits. Earnings per share was 2.96.
- Revenue
- 811.56M
- Gross Profit
- 563.72M
- Operating Income
- 261.04M
- Pretax Income
- 304.89M
- Net Income
- 265.31M
- EBITDA
- 293.18M
- Earnings Per Share (EPS)
- 2.96
Cash Flow
In the last 12 months, operating cash flow was 332.49M and capital expenditures -91.16M, giving a free cash flow of 241.33M billion.
- Operating Cash Flow
- 332.49M
- Free Cash Flow
- 241.33M
- Free Cash Flow per Share
- 4.48
Dividends & Yields
Maxigen Biotech Inc. pays an annual dividend of ―, resulting in a dividend yield of 5.76%
- Dividend Per Share
- ―
- Dividend Yield
- 5.76%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 7.63%
- Earnings Yield
- 15.35%
Stock Price Statistics
- Beta
- 0.31
- 52-Week Price Change
- -17.38%
- 50-Day Moving Average
- 36.98
- 200-Day Moving Average
- 38.56
- Relative Strength Index (RSI)
- 29.95
- Average Volume (3m)
- 75.00K
Important Dates
Maxigen Biotech Inc. upcoming earnings date is Mar 17, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 17, 2027
- Ex-Dividend Date
- ―
Financial Position
Maxigen Biotech Inc. as a current ratio of 3.21, with Debt / Equity ratio of 6.59%
- Current Ratio
- 3.21
- Quick Ratio
- 2.93
- Debt to Market Cap
- 0.03
- Net Debt to EBITDA
- -1.62
- Interest Coverage Ratio
- 6070.74
Taxes
In the past 12 months, Maxigen Biotech Inc. has paid 39.58M in taxes.
- Income Tax
- 39.58M
- Effective Tax Rate
- 0.13
Enterprise Valuation
Maxigen Biotech Inc. EV to EBITDA ratio is 8.27, with an EV/FCF ratio of 10.44.
- EV to Sales
- 3.01
- EV to EBITDA
- 8.27
- EV to Free Cash Flow
- 10.44
- EV to Operating Cash Flow
- 7.57
Balance Sheet
Maxigen Biotech Inc. has TWD 997.26M in cash and marketable securities with TWD 102.25M in debt, giving a net cash position of TWD 895.01M billion.
- Cash & Marketable Securities
- TWD 997.26M
- Total Debt
- TWD 102.25M
- Net Cash
- TWD 895.01M
- Net Cash Per Share
- TWD 9.98
- Tangible Book Value Per Share
- TWD 27.83
Margins
Gross margin is 69.91%, with operating margin of 30.43%, and net profit margin of 34.77%.
- Gross Margin
- 69.91%
- Operating Margin
- 30.43%
- Pretax Margin
- 38.80%
- Net Profit Margin
- 34.77%
- EBITDA Margin
- 36.38%
- EBIT Margin
- 34.77%
Analyst Forecast
The average price target for Maxigen Biotech Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 9.39%
- EPS Growth Forecast
- 39.54%
